A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes

• Published in: Journal of clinical pharmacology Vol. 50; no. 8; p. 861
• Main Authors: Ribbing, Jakob, Hamrén, Bengt, Svensson, Maria K, Karlsson, Mats O
• Format: Journal Article
• Language: English
• Published: England 01.08.2010
• Subjects: Alkanesulfonates - pharmacology; Blood Glucose - metabolism; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2 - physiopathology; Fasting - blood; Humans; Hypoglycemic Agents - pharmacology; Insulin - metabolism; Insulin Resistance - physiology; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Models, Biological; Peroxisome Proliferator-Activated Receptors - agonists; Phenylpropionates - pharmacology; Predictive Value of Tests; Time Factors

Type 2 diabetes mellitus (T2DM) is a progressive, metabolic disorder characterized by reduced insulin sensitivity and loss of beta-cell mass (BCM), resulting in hyperglycemia. Population pharmacokinetic-pharmacodynamic (PKPD) modeling is a valuable method to gain insight into disease and drug action...